𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impact of gemcitabine on the treatment of metastatic pancreatic cancer

✍ Scribed by HIROSHI ISHII; JUNJI FURUSE; MICHITAKA NAGASE; MASAHIRO YOSHINO

Book ID
108949952
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
69 KB
Volume
20
Category
Article
ISSN
0815-9319

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined gemcitabine and radioimmunother
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 116 KB πŸ‘ 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

Resistance of pancreatic cancer to gemci
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis
✍ Bodo Schniewind; Matthias Christgen; Roland Kurdow; Sieglinde Haye; Bernd Kremer πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 426 KB πŸ‘ 1 views

## Abstract Palliative chemotherapy with gemcitabine, a common mode of treatment of pancreatic cancer, has little influence on patients' survival. We investigated the impact of anti‐apoptotic Bcl‐xL protein and its antagonist Bax on gemcitabine‐induced apoptosis in human pancreatic carcinoma cells